Comparative Pharmacology
Head-to-head clinical analysis: ORALONE versus PREDNISOLONE.
Head-to-head clinical analysis: ORALONE versus PREDNISOLONE.
ORALONE vs PREDNISOLONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ORALONE is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties. It binds to the glucocorticoid receptor, leading to modulation of gene expression and inhibition of pro-inflammatory cytokines.
Prednisolone is a glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory cytokines, inhibition of phospholipase A2, and reduction of prostaglandin and leukotriene synthesis.
0.3-0.6 mg/kg IV/IM every 4-6 hours as needed; maximum single dose 30 mg.
Initial adult dose: 5-60 mg orally, intramuscularly, or intravenously daily, divided into 2-4 doses; maintenance: 2.5-15 mg daily.
None Documented
None Documented
Clinical Note
moderatePrednisolone + Digoxin
"Prednisolone may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateMethylprednisolone + Digoxin
"Methylprednisolone may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderatePrednisolone + Digitoxin
"Prednisolone may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateMethylprednisolone + Digitoxin
"Methylprednisolone may decrease the cardiotoxic activities of Digitoxin."
1.5–3 hours (mean 2.5 hours) in adults; prolonged to 3–6 hours in hepatic impairment and up to 4 hours in elderly patients.
Terminal half-life: 2.1-3.5 hours in adults; prolonged in hepatic impairment (up to 12 hours) or with concurrent estrogen use.
Renal: >90% as glucuronide conjugates and unchanged drug (approximately 60% as metabolites, 30% unchanged). Biliary/fecal: <5%.
Renal (primarily as glucuronide and sulfate conjugates; <20% as unchanged prednisolone); biliary/fecal (minor, <5%).
Category C
Category D/X
Corticosteroid
Corticosteroid